STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANNX
  4. [Form 4] Annexon, Inc. Insider Trading Activity

[Form 4] Annexon, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ANNX logo
Annexon, Inc.

NASDAQ:ANNX

ANNX Rankings

#4050 Ranked by Market Cap
N/A Ranked by Dividends

ANNX Latest News

Aug 27, 2025
Annexon Biosciences to Participate in Upcoming September Investor Conferences
Aug 18, 2025
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Aug 14, 2025
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Aug 7, 2025
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
Jul 24, 2025
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

ANNX Latest SEC Filings

Sep 4, 2025
[Form 4] Annexon, Inc. Insider Trading Activity
Aug 14, 2025
[10-Q] Annexon, Inc. Quarterly Earnings Report
Aug 14, 2025
[SCHEDULE 13G/A] Annexon, Inc. SEC Filing
Aug 6, 2025
[SCHEDULE 13G/A] Annexon, Inc. SEC Filing
Aug 1, 2025
[Form 4] Annexon, Inc. Insider Trading Activity

ANNX Stock Data

236.26M
101.86M
0.42%
100.14%
8.76%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRISBANE